

ESCMID/ASM Conference on Drug Development

Meet the Challenge of Antimicrobial Resistance

Scientific Programme

October 4 – 7, 2022

Dublin, Ireland



**Join us today –
our commitment
is infectious!**

**– Become an
ESCMID member**

**– Sign up for
study groups**

Good reasons for membership:

- Society's journal: *CMI*
- Registration discounts for events
- Participation in study groups
- ESCMID Newsletter and Yearbook
- Discounts to other journals
- Access to the eLibrary and membership directory
- Eligibility for ESCMID awards, research grants, observerships and mentorships
- Right to vote and participate in ESCMID

Apply for membership

www.escmid.org/membership

escmidmembership@escmid.org



ESCMID

MANAGING INFECTIONS
PROMOTING SCIENCE

Table of Content

Welcome Address	4
Programme Committee	5
Schedule	6
Conference Objectives	7
Conference Venue	7
Scientific Programme	8
– Tuesday, 4 October 2022	8
– Wednesday, 5 October 2022	9
– Thursday, 6 October 2022	10
– Friday, 7 October 2022	11
Paper Poster Sessions	12
Sponsors	20
ESCMID/ASM Attendance Grants	20
Integrated Symposia	21
Future Congresses	24

Welcome Address

Dear Friends and Colleagues,

It is with pleasure that we welcome you to the 7th meeting of the **ESCMID-ASM Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance**. We are excited to be hosting this conference in-person at last in the incredible city of Dublin in the Republic of Ireland. This follows the cancelled meeting from 2020 and the excellent online meeting from 2021, and provides a great opportunity to finally meet up with old friends, as well as network and make new collaborations.

Whilst AMR continues to remain a global threat, the development of new agents or solutions remains challenging. Investment in this area is more reliant on public-private initiatives, and with fewer large pharmaceutical industries invested in this therapy area, the problem is increasingly shared amongst academics, small biotechs and pharma and some large pharma.

The programme committee has prepared an exciting programme which is focussed on the challenges of developing new agents and solutions for AMR. The programme will start off with a half-day bootcamp, designed to share the wealth of experience from the community. This will be followed by two and a half days of high quality symposia, roundtable discussion and keynote and young investigator lectures.

The meeting is designed to bring together academics, industry, regulators and funders to share experience, collaborate and learn. The meeting will include topics from discovery right through to clinical development and clinical use.

We warmly welcome you to Dublin and thank you for joining us.

Shampa Das

Liverpool, United Kingdom

Co-Chair, Programme Committee (ESCMID)



David Andes

Madison, United States

Co-Chair, Programme Committee (ASM)



Programme Committee




Mark Albrecht
Washington, USA



Paul Ambrose
Schenectady, USA



David Andes
Madison, USA



Christine Årdal
Oslo, Norway



Marc Bonten
Utrecht, Netherlands



Mariana Castanheira
North Liberty, USA



Marco Cavaleri
Amsterdam, Netherlands



Shampa Das
Liverpool, UK



Mike Dawson
Hitchin, UK



Ann Eakin
Waltham, USA



David Hyun
Washington, USA



Sumathi Nambiar
Silver Spring, USA



Maurizio Sanguinetti
Rome, Italy



Ursula Theuretzbacher
Vienna, Austria

& Susanne Paukner
Vienna, Austria

Schedule

Tuesday 4 October 2022	Wednesday 5 October 2022	Thursday 6 October 2022	Friday 7 October 2022
	08:25 – 08:30	08:25 – 08:30	08:25 – 08:30
	Opening and Welcome	Opening and Welcome	Opening and Welcome
	08:30 – 10:00	08:30 – 10:30	08:30 – 10:30
	Symposium 1: Novel Clinical Development pathways 1 – Clinical trial designs	Symposium 4: How do we find new antibacterial classes?	Symposium 7: Preclinical development of nontraditional or novel classes
	10:00 – 10:15		
	Coffee break		
	10:15 – 11:45		
	Symposium 2: Novel Clinical Development pathways 2 – Clinical trial networks	10:30 – 11:00	10:30 – 11:00
		Coffee break	Coffee break
	11:45 – 13:15	11:00 – 12:00	11:00 – 12:00
12:00 – 13:00	Lunch	Young Investigators x2	Keynote Lecture 2: Why are the new drugs not being used?
Integrated Symposium: Challenges and opportunities in the development of non-traditional products in AMR - Organised by CARB-X	12:00 – 13:00 Integrated Symposium: Where resistance spreads: AMR at the community level - Organised by GSK	12:00 – 13:15	12:00 – 13:40
13:00 – 13:05		Lunch	Top Poster Presentations
Opening and Welcome			
13:05 – 15:05			
Bootcamp 1: R&D support – needs and opportunities	13:15 – 15:15	13:15 – 15:15	13:40 – 13:45
	Symposium 3: Clinical development for paediatric patients	Symposium 5: Novel approaches to targeting bacteria	Closing Comments
15:05 – 17:05			13:45 – 15:15
Bootcamp 2 : Discovery and preclinical development challenges	15:15 – 15:45	15:15 – 15:45	Farewell Cocktail
	Coffee break	Coffee break	
	15:45 – 16:45	15:45 – 16:15	
	Keynote Lecture 1: Unmet medical needs	Young Investigators x1	
		16:15 – 17:15	
	17:00 – 18:30	Symposium 6: Drug discovery – beyond the science	
17:05 – 17:10	Wednesday Poster Presentations with Light Reception	17:15 – 18:15	
Closing Comments		Thursday Poster Presentations with Light Reception	
17:15 – 20:15			
Reception Networking Event			

Conference Objectives

Meet the Challenge of Antimicrobial Resistance

Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by national and international bodies. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), this multidisciplinary meeting will address the challenges, opportunities and current requirements for antimicrobial drug development to address antimicrobial resistance.

Conference Venue

Crowne Plaza Dublin - Blanchardstown, an IHG Hotel

Blanchardstown Town Centre, Dublin 15

For any urgencies or questions onsite,
please call Carla Seiler:
+41 79 274 83 49



Scientific Programme

Tuesday, 4 October 2022

12:00 – 13:00 **Integrated Symposium**
 See page 21

13:00 – 13:05 **Opening and Welcome**

13:05 – 15:05 **Bootcamp 1: R&D support –
 needs and opportunities**

Chairs: Ursula Theuretzbacher,
 Mike Dowson
**Challenges of academic drug
 discovery: What would ideal
 support look like?**
 Christopher Dowson
 [Coventry, United Kingdom]
**How to get support: Advice
 for universities and SMEs**
 Silke Alt [Braunschweig, Germany]
**Screening support and
 common data resources to
 aid antibiotic drug discovery**
 Philip Gribbon [Hamburg, Germany]

15:05 – 17:05 **Bootcamp 2 : Discovery and
 preclinical development
 challenges**

Chairs: Mark Albrecht,
 Ursula Theuretzbacher
Characterising a good target
 Heike Brötz-Oesterhelt
 [Tuebingen, Germany]
**Challenges of *in vivo* studies to
 support pre-clinical to clinical
 translation**
 Carina Vingsbo
 [Copenhagen, Denmark]
**Considerations in the safety
 of anti-infectives: target and
 chemistry de-risking**
 James Sidaway
 [Alderley, United Kingdom]

17:05 – 17:10 **Closing Comments**

17:15 – 20:15 **Reception Networking Event**

Bootcamps in collaboration with



Scientific Programme

Wednesday, 5 October 2022

08:25 – 08:30 **Opening and Welcome**

08:30 – 10:00 **Symposium 1: Novel Clinical Development pathways 1 – Clinical trial designs**

Chairs: Marco Cavaleri,
 Sumathi Nambiar
Adaptive design
 Aaron Dane (Macclesfield,
 United Kingdom)
Innovations in clinical trial design
 Sarah Walker
 (London, United Kingdom)
Judging added benefit through HTA
 Colm Leonard
 (Manchester, United Kingdom)

10:00 – 10:15 **Coffee break**

10:15 – 11:45 **Symposium 2: Novel Clinical Development pathways 2 – Clinical trial networks**

Chairs: Marco Cavaleri,
 Sumathi Nambiar
ECRAID
 Marc Bonten
 (Utrecht, Netherlands)
Wellcome Trust's ADVANCE-ID
 David Paterson
 (Brisbane, Australia)
ARLG
 Henry Chambers
 (San Francisco, United States)

11:45 – 13:15 **Lunch**

12:00 – 13:00 **Integrated Symposium**
See page 21

13:15 – 15:15 **Symposium 3: Clinical development for paediatric patients**

Chairs: David Hyun,
 Sumathi Nambiar
Challenges and solutions for pediatric and neonatal clinical efficacy trials (Online)
 Julia Bielicki
 (London, United Kingdom)
Paediatric and neonatal pharmacokinetics and extrapolating between populations
 Michael Neely
 (Los Angeles, United States)
Investigator experience of navigating paediatric and neonatal clinical trials from Industry
 John Bradley
 (San Diego, United States)

15:15 – 15:45 **Coffee break**

15:45 – 16:45 **Keynote Lecture 1: Unmet medical needs**

Chair: Mariana Castanheira
View from South Africa
 Marc Mendelson
 (Cape Town, South Africa)
View from India
 Kamini Walia (New Delhi, India)

17:00 – 18:30 **Wednesday Poster Presentations with Light Reception**

Scientific Programme

Thursday, 6 October 2022

08:25 – 08:30 **Opening and Welcome**

08:30 – 10:30 **Symposium 4: How do we find new antibacterial classes?**

*Chairs: Mike Dawson,
 Ann Eakin*
Overview of approaches to find new leads

*Deborah Hung
 [Cambridge, United States]*

Phenotypic screening for new antibiotics

*Zemer Gitai
 [Princeton, United States]*

Uptake into Gram-negatives

*Helen Zgurskaya
 [Norman, United States]*

Chemical matter for new antibiotic screening

*Heinz Moser
 [San Mateo, United States]*

10:30 – 11:00 **Coffee break**

11:00 – 12:00 **Young Investigators x2**

*Chair: Mike Dawson
 Waheed Adedeji
 [Antwerp, Belgium]
 Phoebe Williams
 [Sydney, Australia]*

12:00 – 13:15 **Lunch**

13:15 – 15:15 **Symposium 5: Novel approaches to targeting bacteria**

*Chairs: Mariana Castanheira,
 Shampa Das*
Use of CRISPR technology
*Dziuginta Jasinskyte
 [Copenhagen, Denmark]*
Antivirulence
*Hasan Jafri
 [San Francisco, United States]*

Immunomodulation

*Mike Westby
 [Sandwich, United Kingdom]*
How to bring a non-traditional therapy to late stage development
*Samareh Azeredo da Silveira
 [Geneva, Switzerland]*

15:15 – 15:45 **Coffee break**

15:45 – 16:15 **Young Investigators x1 (Online)**

*Chair: Ann Eakin
 Vineet Dubey
 [Liverpool, United Kingdom]*

16:15 – 17:15 **Symposium 6: Drug discovery – beyond the science**

*Chairs: David Hyun,
 Mark Albrecht*
Outline of the problem at the bedside/community
*Alison Holmes [London,
 United Kingdom]*
The importance of considering social impact in drug discovery projects
*Ursula Thereutzbacher
 [Vienna, Austria]*
Wellcome's strategic focus on infectious disease and AMR
*Tim Jinks
 [Cambridge, United Kingdom]*
Perspective from PACCARB on incorporating AMR into pandemic preparedness policy [Pre-recorded]
*Jomana Musmar
 [Washington, United States]*

17:15 – 18:15 **Thursday Poster Presentations with Light Reception**

Scientific Programme

Friday, 7 October 2022

08:25 – 08:30 Opening and Welcome

08:30 – 10:30 Symposium 7: Preclinical development of non-traditional or novel classes

Chairs: Shampa Das,
Paul Ambrose

Non-traditional landscape
Erin Duffy
(Boston, United States)

Phage development
Joe Larsen
(Morrisville, United States)

Monoclonal antibodies
Zoltan Magyarics
(Vienna, Austria)

10:30 – 11:00 Coffee break

11:00 – 12:00 Keynote Lecture 2: Why are the new drugs not being used?

Chair: Paul Ambrose

US view
Andrew Shorr
(Washington, United States)

European view
Alison Holmes
(London, United Kingdom)

12:00 – 13:40 Top Poster Presentations

13:40 – 13:45 Closing Comments

13:45 – 15:15 Farewell Cocktail

Paper Poster Sessions

At the ESCMID/ASM conference selected paper posters will be shown during two dedicated poster sessions.

Wednesday, 5 October 2022 17:00 - 18:30

Thursday, 6 October 2022 17:15 - 18:15

During these sessions the presenting author will be standing next to their poster and lively discussions are encouraged. Refreshments and snacks will be offered, while the sessions are taking place, for the presenters and attendees.

Top 10 selected posters will be presented orally during Top Poster Presentations session on Friday, 7 October between 12:00 and 13:40. List of selected posters can be found below:

EA42 - Antibody-antibiotic conjugate for melioidosis – *Adam Taylor*

EA70 - Improving the accuracy of *in vitro* antimicrobial testing with simulated body fluid – *Connagh Redmond*

EA13 - Identifying the network of bactericidal interactions between mycobacterial respiratory chain complexes to develop fast-acting drugs for tuberculosis – *Greg Cook*

EA28 - *In vivo* potency of a novel class of outer membrane protein targeting antibiotic (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA) – *Françoise Jung*

EA15 - Inter-species interactions alter antimicrobial susceptibility in polymicrobial cultures – *Eva Bernadett Benyei*

EA09 - Participant, geographic, and surgical factors are associated with clinical failure in registration-al trials for complicated intraabdominal infection – *Tori Kinamon*

EA19 - Characterisation of novel, non-covalent cyclic peptide (Bicycles®) inhibitors of PBP3s from important Gram-negative pathogens – *Hector Newman*

EA49 - The bacterial itaconate degradation pathway: an immune system evasion mechanism and antimicrobial target – *Jacob Pierscianowski*

EA01 - Time to change the complicated urinary tract infection primary endpoint? The problem and a potential solution – *Paul McGovern*

EA37 - Monoclonal antibodies against BauA and OmpW2 disrupt growth, prevent sepsis, and promote survival of mice infected with *Acinetobacter baumannii* – *Daniel Zurawski*

Paper Poster Sessions

1. Clinical development

Abstract number	Abstract title	Presenter
EA01	Time to change the complicated urinary tract infection primary endpoint? The problem and a potential solution	Paul McGovern
EA02	Population pharmacokinetics of apramycin to support prediction of efficacious dose with first-in-human trial data	Anna Chirkova

2. Drug development

Abstract number	Abstract title	Presenter
EA03	Cefepime-taniborbactam and comparator activity <i>in vitro</i> against carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CRPA) and multidrug-resistant (MDR) Enterobacterales and <i>P. aeruginosa</i> from 2018-2020 surveillance	Greg Moeck
EA04	Biological evaluation of novel phosphonate inhibitors targeting <i>Pseudomonas aeruginosa</i> elastase LasB	Roya Shafiei
EA05	Octapeptins - independent antibiotic agents or antibiotic adjuvants to treat MDR/PmxR Gram-negative bacteria?	Johannes Zuegg
EA06	Developing a novel antimicrobial-phytochemical conjugate with antimicrobial activity against <i>Streptococcus uberis</i>, <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i>	Jian Yang
EA07	A study of restoring tobramycin effectiveness toward resistant Gram-negative bacteria by encapsulate it in liposomal formulation containing methylglyoxal (Lip-MGO-TOB)	Wed Alluhaim
EA08	DNV3837, a parenteral GI tract-targeted treatment for <i>Clostridioides difficile</i> infection	Georges Gaudriault
EA09	Participant, geographic, and surgical factors are associated with clinical failure in registrational trials for complicated intraabdominal infection	Tori Kinamon
EA10	BARDA's Investments and priorities in product development to combat antimicrobial resistance	Jessica Swenson
EA12	Novel dual bacterial topoisomerases inhibitors with broad-spectrum antibacterial activity	Martina Hrast

Paper Poster Sessions

3. Drug discovery		
Abstract number	Abstract title	Presenter
EA13	Identifying the network of bactericidal interactions between mycobacterial respiratory chain complexes to develop fast-acting drugs for tuberculosis	Greg Cook
EA14	Towards the discovery of new DDI inhibitors using a fragment-based drug discovery	Rok Frlan
EA15	Inter-species interactions alter antimicrobial susceptibility in polymicrobial cultures	Eva Bernadett Benyei
EA17	Penicillin binding protein inhibitors of EcPBP3 discovered using a modified phage display platform (Bicycles®)	Nikolaos Bournakas
EA18	Chemical-chemical interaction profiling reveals a Rod complex inhibitor	Rinki Gupta
EA19	Characterisation of novel, non-covalent cyclic peptide (Bicycles®) inhibitors of PBP3s from important Gram-negative pathogens	Hector Newman
EA20	RECCE® 327 demonstrates bactericidal activity against several microbial species	Philip Sutton
EA21	Antibacterial, safety, efficacy and molecular mechanism-of-action of halogenated codonopsinine derivative (HCD1) against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	Saiful Azmi Johari
EA22	Organic derivatives of silichristin elicited potent antibacterial activity against penicillin-binding protein 3 of <i>Pseudomonas aeruginosa</i> in silico	Jamiu Aribisala
EA23	Design of small-molecule drugs to target multiple bacterial tRNA synthetases	Lorenzo Pavanello
EA24	WGS-based dual strategy for the Identification of key targets to enhance beta-lactam activity in <i>Mycobacterium tuberculosis</i>	Francisco Olivença
EA25	Discovery of PK-188 as novel non-competitive inhibitor targeting NDM-1 and VIM metallo-β-lactamases	Vidmantas Petraitis

Paper Poster Sessions

4. New antibacterial classes

Abstract number	Abstract title	Presenter
EA26	Fragment class with carbapenemase inhibition and antibacterial activity	Hannelore Meyer
EA27	<i>In vitro</i> potency and selectivity of a novel class of outer membrane protein targeting antibiotics (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA)	Carolin D'Arco
EA28	<i>In vivo</i> potency of a novel class of outer membrane protein targeting antibiotic (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA)	Françoise Jung
EA29	<i>In vitro</i> bactericidal activity of NOSO 502: a novel action odilorhabdin antibiotic	Alasdair MacGowan
EA30	Antibacterial interactions of NOSO-502 studied by checkerboard method using combinations with amikacin, ciprofloxacin, colistin, meropenem and tigecycline against Enterobacterales	Alasdair MacGowan
EA31	Antimicrobial activity of ceftolozane/tazobactam and imipenem/relebactam in Dutch <i>Pseudomonas aeruginosa</i> isolates obtained from patients at the ICU, Pulmonology and Urology Depts. collected during 10 years of surveillance	Peter Croughs
EA32	Metallobiotics: A new class of antimicrobial agents?	Mark Blaskovich
EA33	Conjugated oligoelectrolytes – a novel antibiotic platform with activity against nontuberculous mycobacteria	Kaixi Zhang

Paper Poster Sessions

5. Non-traditionals

Abstract number	Abstract title	Presenter
EA35	Recurring problems and mitigation strategies in the development of monoclonal antibodies against AMR pathogens: a report from the COMBINE Expert Workshop	Linda Marchioro
EA36	Lysins as promising antibacterial therapeutics against uropathogenic <i>Escherichia coli</i>	Syed Ahmed
EA37	Monoclonal antibodies against BauA and OmpW2 disrupt growth, prevent sepsis, and promote survival of mice infected with <i>Acinetobacter baumannii</i>	Daniel Zurawski
EA39	Cannabidiol (CBD) as novel non-traditional antimicrobial candidate targeting methicillin-resistant and vancomycin-intermediate <i>Staphylococcus aureus</i>	Vidmantas Petraitis

6. Novel therapeutics

Abstract number	Abstract title	Presenter
EA40	<i>P. aeruginosa</i> grown in printable cystic fibrosis model biofilms suitable for high-throughput screening of antibiotics interactions	Goodness Ogechi Osondu-Chuka
EA41	Antisense based anti-adhesive strategy against bacterial urinary tract infection	Elnaz Harifi Mood
EA42	Antibody-antibiotic conjugate for melioidosis	Adam Taylor
EA43	Polymersome encapsulation to enhance antibiotic delivery for the treatment of melioidosis	Kimberley Wright
EA44	Romo1-derived antimicrobial peptide is a new antimicrobial agent against multidrug-resistant bacteria in a murine model of sepsis	Young Do Yoo
EA45	Pharmacodynamics of bacterial efflux pump inhibitors (EPI): proof of concept studies	Alasdair MacGowan
EA46	Activity of the novel engineered antimicrobial peptide PLG0206 against non-fermenting Gram-negative rods	Ian Morrissey

Paper Poster Sessions

6. Novel therapeutics

Abstract number	Abstract title	Presenter
EA47	Organoselenium inhibitors reduce ureolysis and viability of <i>C. neoformans</i> and <i>H. pylori</i>	Agnieszka Grabowiecka
EA48	Ebselen derivatives as picomolar inhibitors of bacterial ureases	Wojciech Tabor
EA49	The bacterial itaconate degradation pathway: an immune system evasion mechanism and antimicrobial target	Jacob Pierscianowski
EA50	A novel, clinically relevant polymyxin, SPR206, eradicates all Gram-negatives associated with wound infection and prevents infection <i>in vivo</i>	Daniel Zurawski
EA51	Using guided antimicrobial peptides to modulate antimicrobial resistance patterns in <i>Helicobacter pylori</i>	Patrick Ortiz
EA52	<i>In vitro</i> efficacy and pharmacodynamics of novel 1,10-phenanthroline-5,6-dione-based metal compounds against <i>Acinetobacter baumannii</i> MDR clinical strains	Ingrid Peregrino
EA53	Efficacy of cefiderocol in experimental <i>Stenotrophomonas maltophilia</i> pneumonia in persistently neutropenic rabbits	Vidmantas Petraitis
EA54	The combination therapy with polymyxin B nonapeptide eradicates persisters	Jihyeon Kim

Paper Poster Sessions

7. Preclinical development

Abstract number	Abstract title	Presenter
EA56	Rapid endpoint method for the quantification of <i>Mycobacterium tuberculosis</i> (Mtb) subjected to three different treatment regimens within the hollow fibre system (HFS)	Stephanie Sandiford
EA57	Pharmacodynamics of WCK 4282 (high dose cefepime plus tazobactam) against β-lactamase producing <i>E. coli</i>	Alasdair MacGowan
EA58	Newly synthesized 5-pyrazolyl substituted 2,4-thiazolidinedione as potential anti-inflammatory and antimicrobial agent	Yulian Konechnyi
EA59	Preclinical development of CRS0393 as a novel antimycobacterial agent that inhibits MmpL3	Urs Ochsner
EA60	A standard protocol for the murine pneumonia model to evaluate treatments for AMR lung infections	Jon Ulf Hansen
EA61	<i>In vivo</i> pharmacodynamic evaluation of meropenem-nacubactam in murine thigh and lung infection models against <i>Klebsiella pneumoniae</i> (KPN) containing OXA-48-like enzymes	Alexander Lepak
EA62	<i>In vivo</i> pharmacodynamic evaluation of CRS0540 in the murine thigh and lung infection models against <i>Staphylococcus aureus</i>	Alexander Lepak
EA63	Preclinical evaluation of apramycin as a drug candidate for <i>Mycobacterium abscessus</i> infections	Sven Hobbie
EA64	Novel bacterial topoisomerase inhibitor gepotidacin demonstrates absence of fluoroquinolone-like arthropathy in juvenile rats	Cindy Fishman
EA64A	Murine vaginal infection models with MDR <i>Neisseria gonorrhoeae</i> isolates for pharmacology studies	Lynn Miesel

Paper Poster Sessions

8. Stewardship

Abstract number	Abstract title	Presenter
EA66	Sticker reminder for IV-to-PO switching of fluoroquinolone therapy; preliminary results of a cluster-randomized controlled trial	Pinyo Rattanaumpawan
EA69	Real-world analysis of new antibiotic use at a US medical center with multi-drug resistant (MDR) <i>Pseudomonas aeruginosa</i> (PSA) but a paucity of carbapenemase-producing Enterobacterales (CPE)	Alexander Lepak
EA69A	Antimicrobial Stewardship in the management of bloodstream infections caused by <i>AmpC</i>-producing Enterobacterales	Elaine Houlihan

9. Other

Abstract number	Abstract title	Presenter
EA70	Improving the accuracy of <i>in vitro</i> antimicrobial testing with simulated body fluid	Connagh Redmond
EA71	BPO: the Bioassay Protocol Ontology, a semantic approach to elevate the reusability of AMR-related drug discovery data	Rakel Arrazuria
EA73	Correlation between antimicrobial resistance and immune-depression in pediatrics: a retrospective study from the Bambino Gesù Children Hospital of Rome	Danielle Domo
EA74	Cd resistance leads antibiotic resistance in bacteria of host and non-host environment	Juoae Chang

Sponsors



ESCMID/ASM Attendance Grants

We are pleased to announce that for the ESCMID/ASM conference we have awarded the following attendees with attendance grants covering a full registration:

Yulian Konechnyi, Lviv, Ukraine
Alexander Lepak, Madison, USA
Francisco Olivença, Lisbon, Portugal
Goodness Osondu-Chuka, Vienna, Austria
Connagh Redmond, Coburg, Australia

Integrated Symposia

CARB-X Medical Symposia

October 4, 2022 - 12:00-13:00 BST



Challenges and opportunities in the development of non-traditional products in AMR

Chair	Maria Uria-Nickelsen , PhD, Alliance Director, CARB-X
ESCMID-appointed Chair	Shampa Das , PhD, Deputy Head of Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool
Speakers	Richard Alm , PhD, Chief Scientist, CARB-X Victor Nizet , MD, Chief of the Division of Host-Microbe Systems and Therapeutics, University of California, San Diego (UCSD) Tomas Doyle , PhD, GlaxoSmithKline David Cook , PhD, Senior Vice President and Chief Scientific Officer, Forma Therapeutics Miriam Furst-Wilmes , PhD, Clinical Assessor for Antiinfectives, DZIF Office for Scientific and Regulatory Advice

GSK Medical Symposia

October 5, 2022 - 12:00-13:00 BST



Where resistance spreads: AMR at the community level

Debating innovative solutions with multiple stakeholders

ESCMID-appointed Chair	Alexander Lepak , University of Wisconsin, Madison, United States
Speakers	Mark Wilcox , PhD, University of Leeds, United Kingdom Rafael Canton , PhD, Complutense University, Madrid, Spain Neil Pearson , GSM R&D, Collegeville, United States Melissa Kramer , uUTI Free Patient Advocate, Ireland

It is an accepted premise, that without innovation and strategies in place, the treatment of drug-resistant infections will become increasingly challenging. Within the community environment, there is the potential for a 'perfect storm' to be created, due to the high volume of antibiotics prescribed in this setting.

WHO define Antimicrobial Resistance (AMR) as a global health and development threat, which requires urgent multisectoral action in order to achieve Sustainable Development Goals.

In this symposium our panel of experts will explore, from different angles, the need for innovative strategies and solutions in the face of AMR, and how collaboratively, industry, public health, healthcare professionals and patients can address this problem to improve outcomes for patients and society.



Summer School

www.escmid.org/profession_career/educational_activities


21st ESCMID Summer School Seville, Spain 3 – 10 July 2023

A one-week course dedicated to postgraduate and continuing medical education. The programme covers a broad range of topics in clinical microbiology and infectious diseases and will interest young MDs at the end of their specialty training as well as biologists, pharmacists, and those researching/practicing in the infection field. Presentations are pitched at a postgraduate educational level.

Please register at
www.escmid.org/profession_career/educational_activities.
Places are limited, apply by 1 June 2023!
Registration opens in January 2023.

Organised by the ESCMID Education Subcommittee





See you in Boston!



ASM/ESCMID

**JOINT CONFERENCE ON DRUG DEVELOPMENT TO MEET
THE CHALLENGE OF ANTIMICROBIAL RESISTANCE**

September 19-22, 2023 • Boston, Massachusetts
asm.org/escmid

Future Congresses

33rd ECCMID

COPENHAGEN, DENMARK

15 – 18 April 2023

Bella Center Copenhagen

34th ECCMID

BARCELONA, SPAIN

27 – 30 April 2024

Fira de Barcelona